R&D models: lessons from vaccine history

Wilson, Paul and Post, Sarah and Srinivas, Smita (2007): R&D models: lessons from vaccine history. Published in: International AIDS Vaccine Initiative Policy Research Working Papers (June 2007)

Abstract

A preventive HIV vaccine offers the best hope for ending the AIDS pandemic. Scientific evidence suggests that an HIV vaccine is possible, and funding for HIV vaccine research and development (R&D) has increased substantially in recent years. The speed of progress toward an HIV vaccine will depend on the management of the effort as well as on its scale, however, and organizational issues have been the subject of vigorous debate. With this paper, we seek to shed light on these debates by examining the history of vaccine development, as well as some examples of large R&D initiatives in other areas. We focus on two issues: the roles of the public and private sectors, and the merits and risks of strong central direction of R&D. We also consider the scientific, regulatory, and institutional changes that complicate extrapolation from past experience to the case of HIV vaccines. Our analysis draws on extensive interviews with experts in the field as well as a literature review.

• Item Type: MPRA Paper
• Language: English
• Keywords: R&D; vaccine; AIDS; public; private;institution
• Subjects: I - Health, Education, and Welfare > I1 - Health; O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights; O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O32 - Management of Technological Innovation and R&D

References

Bailar, J.C. and H.L. Gornik. 1997. “Cancer undefeated.” New England Journal of Medicine 336(22): 1569-1574.

Baker, J.P. 2000. “Immunization and the American way: 4 childhood vaccines.” American Journal of Public Health 90(2): 199-207.

Baker, J.P. and S.L. Katz. 2004. “Childhood vaccine development: an overview.” Pediatric Research 55(2): 347-356.

Blume, S.S. 2005. “Lock in, the state and vaccine development: lessons from the history of polio vaccines.” Research Policy 34(2): 159-173.

Baylor, N.W. and K. Midthun. 2003. “Regulation and testing of vaccines.” In Vaccines, 4th edition. Edited by S.A. Plotkin and W.A. Orenstein. Pp. 1539-56. Philadelphia: W.B. Saunders.

Center for Global Development Advance Market Commitment Working Group. 2005. Making markets for vaccines: ideas to action. Washington: Center for Global Development. Retrieved July 6, 2006, from http://www.cgdev.org/vaccine.

Cohen, J. 2001. Shots in the dark: the wayward search for an AIDS vaccine. New York: W.W. Norton.

Commission on Intellectual Property Rights, Innovation and Public Health. 2006. Public health, innovation and intellectual property rights. WHO, Geneva. Retrieved November 10, 2006, from http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf.

Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. 2005. “The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan.” PLoS Medicine 2(2): e25. Retrieved January 4, 2007, from http://dx.doi.org/10.1371/journal.pmed.0020025.

Department of Defense. 1998. Addressing emerging infectious disease threads: a strategic plan for the Department of Defense. Washington: Walter Reed Army Institute of Research. Retrieved November 20, 2006, from http://www.geis.fhp.osd.mil/GEIS/aboutGEIS/historicaldocs/1998%20-%205Year.asp.

Douglas, R.G. 2003. “The vaccine industry.” In Vaccines, 4th edition. Edited by S.A. Plotkin and W.A. Orenstein. Pp. 47-51. Philadelphia: W.B. Saunders.

Frantz, F. 2006. “Pipeline problems are increasing the urge to merge.” Nature Reviews Drug Discovery 5: 977-979. Retrieved November 1, 2006, from http://www.nature.com/nrd/journal/v5/n12/full/nrd2206.html.

Galambos, L. and J.E. Sewell. 1995. Networks of innovation: vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995. Cambridge, U.K.: Cambridge University Press.

GlaxoSmithKline. 2005. GlaxoSmithKline reviews pipeline of novel vaccines with the potential to dramatically improve global health. Retrieved October 8, 2006, from http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=601.

Global HIV Vaccine Enterprise. 2005. “Promoting innovation and collaboration to speed the search for an HIV vaccine. ” Enterprise brochure. Retrieved April 20, 2006, from http://www.hivvaccineenterprise.org/_dwn/entperprise_brochure_oct_2005.pdf.

Gosling, F.G. 1999. The Manhattan Project: making the atomic bomb. Washington: Department of Energy. Retrieved October 15, 2006, from http://www.atomicarchive.com/History/mp/index.shtml.

Hilleman, M.R. 1998. “A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS.” Vaccine 16(8): 778-793.

Hilleman, M.R. 1999. “Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology.” Immunological Reviews 170: 7-27.

Hilleman, M.R. 2000. “Vaccines in historic evolution and perspective: a narrative of vaccine discoveries.” Vaccine 18(15): 1436-1447.

Hilleman, M.R. 2002. “Vaccines and the vaccine enterprise: historic and contemporary view of a scientific initiative of complex dimensions.” In The Jordan Report: accelerated development of vaccines 2002. Pp. 24-30. Washington: National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Health and Human Services.

HIV Vaccines and Microbicides Resource Tracking Working Group. 2006. Adding it all up: HIV vaccine and microbicide development funding: 2000 to 2005. Retrieved September 30, 2006, from http://hivresourcetracking.org/content/RT_2006_Report_FINAL.pdf.

Hoyt, K. 2006. “Vaccine innovation: lessons from World War II.” Journal of Public Health Policy 27(1): 38-57.

International AIDS Vaccine Initiative (IAVI). 2006. AIDS Vaccine Blueprint 2006: Actions to strengthen global research and development. New York: IAVI. Retrieved September 12, 2006, from http://www.iavi.org/viewfile.cfm?fid=41059.

Immunization Action Coalition. 2003. Vaccines and biologics used in US and foreign markets. Retrieved March 30, 2006, from http://www.immunize.org/izpractices/p5120.pdf.

Immunization Action Coalition. 2006. Historic dates and events related to vaccines and immunization. Retrieved April 18, 2006, from http://www.immunize.org/timeline/.

Inglis, S., A. Shaw, and S. Koenig. 2006. “HPV vaccines: commercial research and development.” Vaccine 24(S3): S3/99-S3/105.

Institute of Medicine (IOM). 2004. Financing vaccines in the 21st century: assuring access and availability. Washington: National Academies Press.

Johnson, R.C., C. Kodner, and M. Russell. 1986. “Passive immunization of hamsters against experimental infection with the Lyme disease spirochete.” Infection and Immunity 53(3): 713-714.

Lowy, D.R. and J.T. Schiller. 2006. “Prophylactic human papillomavirus vaccines.” Journal of Clinical Investigation 116(5): 1167-1173.

Mitchell, V.S., N.M. Philipose, and J.P. Sanford. eds. 1993. The Children's Vaccine Initiative: achieving the vision. Washington: National Academy Press.

Mahoney, R.T., A. Pablos-Mendez, and S. Ramachandran. 2003. “The introduction of new vaccines into developing countries: the role of intellectual property.” Vaccine 22(5-6): 786-792.

McGeary, M. 2003. The National Cancer Program: enduring issues. Washington: Institute of Medicine. Retrieved October 1, 2006, from http://www.iom.edu/CMS/3798/12774/12822.aspx?printfriendly=true.

McNeil, C. 2006. “Who invented the VLP cervical cancer vaccines?” Journal of the National Cancer Institute 98(7): 433.

McNeil, D.G. 2006. “How a vaccine search ended in triumph.” New York Times, 29 August 2006.

Meldrum, M. 1998. “‘A calculated risk’: The Salk polio vaccine field trials of 1954.” British Medical Journal 317(7167): 1233-1236.

Moran, M., A. Ropars, J. Guzman, J. Diaz, and C. Garrison. 2005. The new landscape of neglected disease drug development. London: Pharmaceutical R&D Policy Project. National Cancer Institute. 2006. National Cancer Act of 1971. Retrieved October 1, 2006, from http://dtp.nci.nih.gov/timeline/noflash/milestones/M4_Nixon.htm.

National Immunization Program. 2006. Epidemiology and prevention of vaccinepreventable diseases. 9th edition. Atlanta: Centers for Disease Control and Prevention.

National Institute of Allergy and Infectious Diseases (NIAID). 2002. The Jordan Report: accelerated development of vaccines. Washington: U.S. Department of Health and Human Services.

National Institutes of Health Office of Budget. 2006. NIH spending history. Retrieved January 4, 2007, from http://officeofbudget.od.nih.gov/PDF/1993%20-%202005%20Mech%20Tables.pdf.

National Vaccine Advisory Committee. 1999. “Lessons learned from a review of the development of selected vaccines.” Pediatrics 104(4): 942-950.

Nichols, R.W. 1971. “Mission-oriented R&D.” Science 172(3978): 29-37.

Pearce, J.M.S. 2004. “Salk and Sabin: poliomyelitis immunization.” Journal of Neurology, Neurosurgery, and Psychiatry 75(11): 1552.

Pérez, A., F. Dickinson, A. Baly, and M. Martinez. 1999. “The epidemiological impact of antimeningococcal B vaccination in Cuba.” Memorias de Instituto Oswaldo Cruz 94(4): 433-440.

Plotkin, S.A. 2005. “Vaccines: past, present, and future.” Nature Medicine Supplement 11(4): S5-S11.

President’s Cancer Panel. 1999. Statements from the President’s Cancer Panel meeting. Retrieved December 1, 2006, from http://deainfo.nci.nih.gov/ADVISORY/pcp/19jul99.htm.

Rader, R.A. 2006. Biopharmaceutical products in the US and European markets. 6th edition. Rockville, MD: BioPlan Associates. Retrieved February 1, 2007, from http://www.biopharma.com.

Rappuoli, R., H.I. Miller, and S. Falkow. 2002. “The intangible value of vaccination.” Science 297(5583): 937.

Rettig, R.A. 1977. Cancer crusade: the story of the National Cancer Act of 1971. Princeton, NJ: Princeton University Press.

Robbins, F.C. 2003. “The history of polio vaccine development.” In Vaccines, 4th edition. Edited by S.A. Plotkin and W.A. Orenstein. Pp. 17-30. Philadelphia: W.B. Saunders.

Sheridan, C. 2005. “The business of making vaccines.” Nature Biotechnology 23(11): 1359-1366.

Struck, M.M. 1996. “Vaccine R&D success rates and development times.” Nature Biotechnology 14(5): 591-593.

Thanassi, W.T. and R.T. Schoen. 2000. “The Lyme disease vaccine: conception, development, and implementation.” Annals of Internal Medicine 132(8): 661-668.

Thorsteinsdottir, H. et al. 2006. “Health biotechnology publishing takes off in developing countries.” International Journal of Biotechnology 8(1-2): 23-42. Retrieved November 2, 2006, from http://www.inderscience.com/search/index.php?action=record&rec_id=8962&prevQuery=&ps=10&m=or.

UNAIDS. 2006. 2006 Report on the Global AIDS epidemic. Geneva: UNAIDS. Retrieved October 10, 2006, from http://www.unaids.org/en/HIV_data_2006GlobalReport/default.asp.

United States P.L. 92-218. 1971. “The National Cancer Act of 1971,” 92nd Congress, S. 1828. Retrieved December 1, 2006, from http://www3.cancer.gov/legis/1971canc.html.